Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

1 Apr 1993

Abstract excerpt

Two Norwegian patients with chronic tyrosinemia type I showed > 50% residual fumarylacetoacetase activity in liver samples obtained during liver transplantation. The enzyme characteristics of both patients were comparable with those of a normal control. Immunohistochemistry on liver sections from these patients and from three other Norwegian tyrosinemia patients revealed a mosaicism of fumarylacetoacetase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes and associated disorders
Share to Diet and metabolism studies
Share to Metabolism and Genetic Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 8473520
DOI: 10.1172/jci116393

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.PMID 8473520Read ↗

Diagnosis and management of tyrosinemia type I.Semantic proximity Read ↗

Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.Semantic proximity Read ↗

Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia.Semantic proximity Read ↗

Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).Semantic proximity Read ↗

No evidence of maternal cell colonization in reverted liver nodules of tyrosinemia type I patients.Semantic proximity Read ↗

Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.Semantic proximity Read ↗

In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I.Semantic proximity Read ↗

Hereditary tyrosinaemia type I: from basics to progress in treatment.Semantic proximity Read ↗

<i>Ex Vivo</i> Hepatic Gene Therapy of a Mouse Model of Hereditary Tyrosinemia Type ISemantic proximity Read ↗

Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.Semantic proximity Read ↗

A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.Semantic proximity Read ↗

Long-term outcome of living donor liver transplantation in a Thai boy with hereditary tyrosinemia type I: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.